Renalytix AI (GB:RENX) has released an update.
Renalytix AI has announced that Medicare has approved a final Local Coverage Determination for its kidneyintelX.dkd test, effective from August 1, 2024, at a rate of $950 per test. This coverage, along with FDA authorization and inclusion in clinical guidelines, positions the company to become a standard in preventative medicine for diabetes and kidney disease in the US. CEO James McCullough anticipates that this will lead to broader insurance coverage and hasten the adoption of the test.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
